Associated Papers
TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study.
Huang Y et al.
Precision Clinical Medicine, 2024
Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital.
Inagaki C et al.
Cancers, 2021
Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms.
Kim B et al.
Plos One, 2019
Multigene testing of moderate-risk genes: be mindful of the missense.
Young EL et al.
Journal of Medical Genetics, 2016
26787654 (PubMed )
Supplement: jmedgenet-2015-103398-s2.pdf
RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
Le Calvez-Kelm F et al.
Plos One, 2012
Select a paper to view details